These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24495942)

  • 41. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects.
    Hartmann JT; Haap M; Kopp HG; Lipp HP
    Curr Drug Metab; 2009 Jun; 10(5):470-81. PubMed ID: 19689244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its therapeutic potential in the treatment of metastatic colorectal carcinoma and advanced gastrointestinal stromal tumors.
    Thangaraju P; Singh H; Chakrabarti A
    Indian J Cancer; 2015; 52(3):257-60. PubMed ID: 26905101
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
    Pariente A; Etcharry F; Cales V; Laborde Y; Ferrari S; Biour M
    Eur J Gastroenterol Hepatol; 2006 Jul; 18(7):785-7. PubMed ID: 16772838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
    Shirley M; Keating GM
    Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China.
    Shi YN; Li Y; Wang LP; Wang ZH; Liang XB; Liang H; Zhang L; Li B; Fan LQ; Zhao Q; Ma ZX; Zhao XF; Zhang ZD; Liu Y; Tan BB; Wang D; Wang LL; Hao YJ; Jia N
    Medicine (Baltimore); 2017 Nov; 96(46):e8240. PubMed ID: 29145240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imatinib in advanced gastrointestinal stromal tumour: when is 800 mg the correct dose?
    Judson I
    Curr Opin Oncol; 2008 Jul; 20(4):433-7. PubMed ID: 18525340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
    Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
    Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
    Van Glabbeke M; Verweij J; Casali PG; Simes J; Le Cesne A; Reichardt P; Issels R; Judson IR; van Oosterom AT; Blay JY
    Eur J Cancer; 2006 Sep; 42(14):2277-85. PubMed ID: 16876399
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
    J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
    Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
    Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
    Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
    Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
    Xu J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.
    Wolter P; Schöffski P
    Acta Oncol; 2010; 49(1):13-23. PubMed ID: 19900123
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
    Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
    Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors].
    Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):801-806. PubMed ID: 31550816
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Efficacy and Safety of Different Regimens of Advanced Gastrointestinal Stromal Tumors After Failure Prior Tyrosine Kinase Inhibitors: A Network Meta-Analysis.
    Zhang X; Liang Y; Li Y; Yin J
    Adv Ther; 2021 Jan; 38(1):399-412. PubMed ID: 33131035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors.
    van Elst JM; IJzerman NS; Mathijssen RHJ; Steeghs N; Reyners AKL; de Haan JJ
    Support Care Cancer; 2022 Mar; 30(3):2307-2315. PubMed ID: 34727226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.